TransCode's TTX-MC138 Shows Durable Disease Control in Phase 1a Trial
Event summary
- 71.4% of 14 efficacy-evaluable patients achieved stable disease in Phase 1a trial of TTX-MC138.
- 36.7% maintained disease control through six months, with three patients progression-free at one year.
- No dose-limiting toxicities reported across evaluated dose levels, including 4.8 mg/kg.
- Exploratory RNA-sequencing showed treatment-associated antitumor immune activation.
- Primary endpoint of the study was met as of September 1, 2026.
The big picture
TransCode's updated Phase 1a data for TTX-MC138 reinforces the potential of targeting miR-10b in advanced solid tumors. The durable disease control and acceptable tolerability profile position the therapy for further evaluation in molecularly defined patient populations. The convergence of clinical and biomarker evidence strengthens the mechanistic rationale, aligning with broader trends in precision immuno-oncology.
What we're watching
- Dose Expansion Strategy
- How TransCode will design dose-expansion strategies to confirm activity in selected cancers and molecularly defined patient populations.
- Biomarker Confirmation
- Whether the exploratory biomarker findings will be confirmed in larger studies, supporting the mechanistic rationale for targeting miR-10b.
- Clinical Development Pace
- The pace at which TransCode advances TTX-MC138 into Phase 2a trials and incorporates updated clinical findings into regulatory submissions.
Related topics